Search

Displaying results 3461 - 3470 of 7687 in total
  1. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system.

  2. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    MAXY-G34 is a pegylated variant of human granulocyte-colony stimulating factor (G-CSF). This variant contains multiple non-naturally occurring lysines that have been introduced into alpha helixes of wild type human G-CSF as PEGylation si...

  3. Drug

    Pilaralisib

    go.drugbank.com/drugs/DB11772
    Investigational

    Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).

  4. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757] … CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene.

  5. Drug

    Gliclazide

    go.drugbank.com/drugs/DB01120
    ApprovedInvestigational

    Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk.

    Products: Nu-gliclazide
  6. Drug

    Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB10076
    Approved

    *H. influenzae* is a Gram-negative coccobacillus that can cause infections including sepsis and meningitis.

  7. Drug

    Romidepsin

    go.drugbank.com/drugs/DB06176
    ApprovedInvestigational

    Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.

  8. Drug

    Tallimustine

    go.drugbank.com/drugs/DB15466
    Experimental

    Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA. … [A182039,A182045] Newer generations of DNA minor groove binding agents can more specifically recognize base pair sequences.[A182051]

  9. Drug

    Efinaconazole

    go.drugbank.com/drugs/DB09040
    ApprovedInvestigational

    Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North ...

  10. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. It is developed by MedImmune for the treatment of Allergic Rhinitis.